期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 14, 期 11, 页码 1521-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2016.05.026
关键词
Pancreatitis; ERCP; Stents; Medications; Prevention
资金
- Cook Medical
Over the past 2 decades, it increasingly has been recognized that endoscopic retrograde cholangiopancreatography (ERCP) is the most predictable provocateur of acute pancreatitis, with an incidence of more than 15% in high-risk patients. For this reason, there has been considerable interest in the effect of periprocedural drug administration as well as different ERCP techniques on both the incidence and severity of post-ERCP pancreatitis. Although many agents and techniques have shown promise in small clinical studies, the majority of these have failed to yield consistent benefit in larger randomized patient groups. This review summarizes the data on medications and ERCP techniques that have been studied for the prevention of post-ERCP pancreatitis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据